"U.S. Food and Drug Administration (FDA) approved JANUVIA(TM) (sitagliptin phosphate), the first and only DPP-4 inhibitor available in the United States for the treatment of type 2 diabetes. JANUVIA has been approved as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones (TZDs), to improve blood sugar (glucose) control in patients with type 2 diabetes when diet and exercise is not enough. The recommended dose of JANUVIA is 100 mg once daily. JANUVIA should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis, as it would not be effective in these settings."
Showing posts with label FDA. Show all posts
Showing posts with label FDA. Show all posts
Wednesday, October 18, 2006
FDA Approves Once-Daily JANUVIA(TM), the First and Only DPP-4 Inhibitor Available in the United States for Type 2 Diabetes - AlphaTrade FN
Labels:
Diabetes,
FDA
0
comments
Subscribe to:
Posts (Atom)
• Key Players in the Plame Affair
